Correlation between tenofovir drug levels and the renal biomarkers RBP-4 and ß2M in the ION-4 study cohort
A Chan, L Park, LF Collins, C Cooper… - Open forum …, 2019 - academic.oup.com
Background Concomitant dosing of ledipasvir (LDV) and tenofovir disoproxil fumarate (TDF)
results in an increased tenofovir (TFV) area under the curve (AUC). The aim of this study …
results in an increased tenofovir (TFV) area under the curve (AUC). The aim of this study …
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center …
Background Tenofovir disoproxil fumarate (TDF) has a strong antiviral effect, but TDF is
known to cause renal dysfunction. Therefore, we are investigating preventing renal …
known to cause renal dysfunction. Therefore, we are investigating preventing renal …
Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana
Background HIV infection is associated with increased risk of renal dysfunction, including
tubular dysfunction (TD) related to antiretroviral therapy (ART). Tenofovir disoproxil fumarate …
tubular dysfunction (TD) related to antiretroviral therapy (ART). Tenofovir disoproxil fumarate …
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients
T Nishijima, H Komatsu, H Gatanaga, T Aoki… - PloS one, 2011 - journals.plos.org
Background Treatment with tenofovir is sometimes associated with renal dysfunction.
Limited information is available on this side effect in patients with small body weight …
Limited information is available on this side effect in patients with small body weight …
[HTML][HTML] Inflammatory properties of tenofovir in human liver cells
S Vazi, S van Zyl, R Vorster-de Wet, C Tiloke - Health Sciences Review, 2023 - Elsevier
ABSTRACT BACKGROUND Tenofovir is one of the antiretroviral (ARV) drugs used as a first-
line regimen known to suppress HIV viral load successfully. However, its clinical application …
line regimen known to suppress HIV viral load successfully. However, its clinical application …
[HTML][HTML] Comparison of renal function between tenofovir disoproxil fumarate and other nucleos (t) ide reverse transcriptase inhibitors in patients with hepatitis B virus …
MG Fischer, W Newman, K Hammer, M Rohrich… - Federal …, 2021 - ncbi.nlm.nih.gov
Background Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) have
become a standard treatment for both HIV and hepatitis B virus (HBV) infections. Tenofovir …
become a standard treatment for both HIV and hepatitis B virus (HBV) infections. Tenofovir …
Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review
F Zhao, H Lu - BioScience Trends, 2024 - jstage.jst.go.jp
Antiretroviral therapy (ART) has significantly enhanced the outlook for people with HIV
(PWH), yet certain ART medications can adversely affect the renal function of these patients …
(PWH), yet certain ART medications can adversely affect the renal function of these patients …
Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide …
K Abe, J Imamura, A Sasaki, T Suzuki, S Kamio… - … Health Care and …, 2024 - Springer
Background Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug,
causes renal function decline and tubular damage in individuals with HIV. While tenofovir …
causes renal function decline and tubular damage in individuals with HIV. While tenofovir …
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine
A Mwafongo, K Nkanaunena, Y Zheng, E Hogg… - Aids, 2014 - journals.lww.com
Objectives: Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency.
Co-administration with boosted protease inhibitors, which increases its exposure, may …
Co-administration with boosted protease inhibitors, which increases its exposure, may …
Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and …
X Zhao, K Sun, Z Lan, W Song, L Cheng, W Chi… - Scientific reports, 2017 - nature.com
Despite the therapeutic success of tenofovir (TFV) for treatment of HIV-1 infection, numerous
cases of nephrotoxicity have been reported. Mitochondrial toxicity has been purported as the …
cases of nephrotoxicity have been reported. Mitochondrial toxicity has been purported as the …